| Species Reactivity | Human |
| Clone | Bexmarilimab |
| Source/Isotype | Human IgG4, Kappa |
| Application | / |
| Specificity | Detects STAB1 |
| Gene | STAB1 |
| Other Names | CLEVER-1, FEEL-1, FEEL1, FELE-1, FEX1, HRFT, SCARH2, STAB-1 |
| Gene ID | 23166 (human) |
| Background | Bexmarilimab is an investigational immunotherapy, the development of which stems from the in-depth exploration of the mechanisms of immunosuppression in the tumor microenvironment. Tumor-associated macrophage often maintains immunosuppression by expressing Clever-1 receptor (also known as Stabilin-1) to help cancer cells evade immune surveillance. Bexmarilimab acts as a humanized anti-Clever-1 IgG4 antibody that, by blocking this receptor, reprograms macrophages from a tumor-promoting M type 2 to an antitumor M Type 1, activates the immune system and enhances sensitivity to standard treatments. The drug shows potential in hematological neoplasms such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) , with a 76% remission rate in high-risk MDS patients and a good safety profile in combination with azacitidine, has been approved by the FDA as an orphan drug. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | Bexmarilimab |
| Source/Isotype | Human IgG4, Kappa |
| Application | / |
| Specificity | Detects STAB1 |
| Gene | STAB1 |
| Other Names | CLEVER-1, FEEL-1, FEEL1, FELE-1, FEX1, HRFT, SCARH2, STAB-1 |
| Gene ID | 23166 (human) |
| Background | Bexmarilimab is an investigational immunotherapy, the development of which stems from the in-depth exploration of the mechanisms of immunosuppression in the tumor microenvironment. Tumor-associated macrophage often maintains immunosuppression by expressing Clever-1 receptor (also known as Stabilin-1) to help cancer cells evade immune surveillance. Bexmarilimab acts as a humanized anti-Clever-1 IgG4 antibody that, by blocking this receptor, reprograms macrophages from a tumor-promoting M type 2 to an antitumor M Type 1, activates the immune system and enhances sensitivity to standard treatments. The drug shows potential in hematological neoplasms such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) , with a 76% remission rate in high-risk MDS patients and a good safety profile in combination with azacitidine, has been approved by the FDA as an orphan drug. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
